Big step forward in launching OX124 in the US UPPSALA, Sweden, Nov. 2, 2023 /PRNewswire/ — Q3 2023 highlights › Total net revenues of SEK 156.1 m (161.0) › EBITDA of SEK -9.5 m (-32.4), EBITDA excluding costs for legal processes and external non-repeating clinical trials, SEK 13.3 m…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.